KDR and cancer: To further examine the clinical implications of high miR-96 and low PTEN levels, we analyzed the survival in the KIRC cohort, although the patients were treated with different kinds of anti-cancer drugs including VEGFR inhibitors (sunitinib, sorafenib, or pazopanib) and rapalogues (sirolimus or temsirolimus).